- Home
- AZI vs CUE Comparison
AZI vs CUE Comparison
Compare AZI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AZI | CUE |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2M | 49.6M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AZI | CUE |
|---|---|---|
| Price | $1.62 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 795.2K | 249.2K |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,466,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.90 | N/A |
| 52 Week Low | $1.62 | $0.47 |
| 52 Week High | $69.00 | $1.75 |
Technical Indicators
Market Signals| Indicator | AZI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 96.66 | 29.93 |
| Support Level | $0.03 | $0.47 |
| Resistance Level | $0.06 | $0.51 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 73.30 | 10.78 |
Price Performance
Historical ComparisonAbout AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.